Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3332MR)

This product GTTS-WQ3332MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3332MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11575MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ1878MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ13440MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ4463MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ9374MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ16018MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ15547MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ6984MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ETI-204
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW